Zalicus Inc (ZLCS) 1.18 $ZLCS
EPIRUS Biopharmaceuticals Reports Third Quarter Results and Provides Corporate Update
Business Wire - Mon Nov 10, 3:30PM CST
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today provided a corporate update and reported financial results for the third quarter ended September 30, 2014.
ZLCS: 1.18 (+0.03), EPRS: 7.67 (+0.67)
Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. to Serve on EPIRUS Board of Directors
Business Wire - Tue Jul 15, 10:49AM CDT
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced that Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. will serve on its board of directors. The board, which was reconstituted today following the company's merger with Zalicus Inc. (Zalicus, NASDAQ: ZLCS), also includes Amit Munshi, Geoffrey Duyk, Scott Rocklage, J. Kevin Buchi and Daotian Fu.
CRME: 9.76 (-0.14), TRVN: 5.42 (+0.15), AVNR: 16.96 (unch), ZLCS: 1.18 (+0.03), IRWD: 15.15 (-0.85), CBST: 101.94 (+0.14), EPRS: 7.67 (+0.67)
EPIRUS and Zalicus Complete Merger - Combined Company Will Trade as EPIRUS Biopharmaceuticals, Inc. (NASDAQ: EPRS)
Business Wire - Tue Jul 15, 10:47AM CDT
--EPIRUS reconstitutes Board of Directors to include Mark H.N. Corrigan, M.D., Julie H. McHugh, William Hunter, M.D., Amit Munshi, Geoffrey Duyk, Scott Rocklage, J. Kevin Buchi and Daotian Fu
ZLCS: 1.18 (+0.03), EPRS: 7.67 (+0.67)
Zalicus and Epirus Agree Zalicus Stockholders to Own 19% of Combined Company Post-Merger
Business Wire - Wed Jun 25, 7:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS) ("Zalicus"
, and Epirus Biopharmaceuticals, Inc. ("Epirus" agreed today that Zalicus stockholders will own 19% of the combined company post-merger. Pursuant to its merger agreement with Epirus Biopharmaceuticals, Inc., the percentage of the combined company that Zalicus stockholders will own as of the closing of the merger was subject to adjustment at the closing based on the level of Zalicus' net cash as of a determination date prior to the closing. Based on Zalicus' current level of net cash, both companies have agreed that stockholders of Zalicus will own approximately 19% of the combined company and current Epirus equityholders will own approximately 81% of the Company following the merger.
ZLCS: 1.18 (+0.03)
Anabios Licenses Sodium Channel Blocking Pain Therapeutic Portfolio from Zalicus
PRWeb - Thu Jun 19, 3:16AM CDT
AnaBios Corporation announced today the licensing of a portfolio of novel preclinical, sodium channel blocking pain therapeutics from Zalicus Inc. The agreement is aimed at accelerating the successful development of new selective sodium channel blockers by employing AnaBios' proprietary Phase X™ technology. Under the terms of the agreement, AnaBios acquires an exclusive license for all development and commercialization rights related to Zalicus' Nav1.7 portfolio of compounds, having a projected commercial market of at least $1.5B annually. In addition, Zalicus will be eligible for future clinical and regulatory milestone payments from AnaBios and the two companies will share in royalty payments based upon any potential future product sales.
ZLCS: 1.18 (+0.03)
Zalicus Licenses Sodium Channel Pain Modulation Program
Business Wire - Wed Jun 18, 7:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has licensed its Sodium Channel Modulator program, including intellectual property and related pipeline assets, to AnaBios Corporation in exchange for clinical milestone payments and royalties on potential future sales. Under the terms of the agreement Zalicus will be eligible to receive up to $17.2 million in clinical and regulatory milestone payments and up to 12% of net sales on any future products resulting from this license.
ZLCS: 1.18 (+0.03)
Sales, Clinical Hold Removal, Trial Initiations, and Committee Recommendations - Analyst Notes on Geron, Zalicus, Northwest Biotherapeutics, Progenics and TG Therapeutics
PR Newswire - Tue Jun 17, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Geron Corporation (NASDAQ: GERN), Zalicus Inc. (NASDAQ: ZLCS), Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) and TG Therapeutics, Inc. (NASDAQ: TGTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3775-100free.
PGNX: 5.66 (+0.06), NWBO: 6.07 (+0.13), ZLCS: 1.18 (+0.03), GERN: 3.03 (unch), TGTX: 13.13 (-0.19)
Short Squeeze Starting in Zalicus (ZLCS) According to WealthMakers.com Report
M2 - Fri Jun 13, 6:54AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a research report on Zalicus (NASDAQ: ZLCS). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $1.49 and the projected fundamental valuation of $6.60.
ZLCS: 1.18 (+0.03)
Why Zalicus (ZLCS) Stock Is Surging Today
at The Street - Thu Jun 12, 10:10AM CDT
Zalicus (ZLCS) surged Thursday after Epirus Switzerland announced clinical data from a Phase 3 study of BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis.
ZLCS: 1.18 (+0.03)
EPIRUS Biopharmaceuticals Reports Third Quarter Results and Provides Corporate Update
Business Wire - Mon Nov 10, 3:30PM CST
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ:EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, today provided a corporate update and reported financial results for the third quarter ended September 30, 2014.
ZLCS: 1.18 (+0.03), EPRS: 7.67 (+0.67)
Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. to Serve on EPIRUS Board of Directors
Business Wire - Tue Jul 15, 10:49AM CDT
EPIRUS Biopharmaceuticals, Inc. (EPIRUS, NASDAQ: EPRS), a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced that Mark H.N. Corrigan, M.D., Julie H. McHugh, and William Hunter, M.D. will serve on its board of directors. The board, which was reconstituted today following the company's merger with Zalicus Inc. (Zalicus, NASDAQ: ZLCS), also includes Amit Munshi, Geoffrey Duyk, Scott Rocklage, J. Kevin Buchi and Daotian Fu.
CRME: 9.76 (-0.14), TRVN: 5.42 (+0.15), AVNR: 16.96 (unch), ZLCS: 1.18 (+0.03), IRWD: 15.15 (-0.85), CBST: 101.94 (+0.14), EPRS: 7.67 (+0.67)
EPIRUS and Zalicus Complete Merger - Combined Company Will Trade as EPIRUS Biopharmaceuticals, Inc. (NASDAQ: EPRS)
Business Wire - Tue Jul 15, 10:47AM CDT
--EPIRUS reconstitutes Board of Directors to include Mark H.N. Corrigan, M.D., Julie H. McHugh, William Hunter, M.D., Amit Munshi, Geoffrey Duyk, Scott Rocklage, J. Kevin Buchi and Daotian Fu
ZLCS: 1.18 (+0.03), EPRS: 7.67 (+0.67)
Zalicus and Epirus Agree Zalicus Stockholders to Own 19% of Combined Company Post-Merger
Business Wire - Wed Jun 25, 7:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS) ("Zalicus"
, and Epirus Biopharmaceuticals, Inc. ("Epirus" agreed today that Zalicus stockholders will own 19% of the combined company post-merger. Pursuant to its merger agreement with Epirus Biopharmaceuticals, Inc., the percentage of the combined company that Zalicus stockholders will own as of the closing of the merger was subject to adjustment at the closing based on the level of Zalicus' net cash as of a determination date prior to the closing. Based on Zalicus' current level of net cash, both companies have agreed that stockholders of Zalicus will own approximately 19% of the combined company and current Epirus equityholders will own approximately 81% of the Company following the merger. ZLCS: 1.18 (+0.03)
Anabios Licenses Sodium Channel Blocking Pain Therapeutic Portfolio from Zalicus
PRWeb - Thu Jun 19, 3:16AM CDT
AnaBios Corporation announced today the licensing of a portfolio of novel preclinical, sodium channel blocking pain therapeutics from Zalicus Inc. The agreement is aimed at accelerating the successful development of new selective sodium channel blockers by employing AnaBios' proprietary Phase X™ technology. Under the terms of the agreement, AnaBios acquires an exclusive license for all development and commercialization rights related to Zalicus' Nav1.7 portfolio of compounds, having a projected commercial market of at least $1.5B annually. In addition, Zalicus will be eligible for future clinical and regulatory milestone payments from AnaBios and the two companies will share in royalty payments based upon any potential future product sales.
ZLCS: 1.18 (+0.03)
Zalicus Licenses Sodium Channel Pain Modulation Program
Business Wire - Wed Jun 18, 7:30AM CDT
Zalicus Inc. (Nasdaq Capital Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has licensed its Sodium Channel Modulator program, including intellectual property and related pipeline assets, to AnaBios Corporation in exchange for clinical milestone payments and royalties on potential future sales. Under the terms of the agreement Zalicus will be eligible to receive up to $17.2 million in clinical and regulatory milestone payments and up to 12% of net sales on any future products resulting from this license.
ZLCS: 1.18 (+0.03)
Sales, Clinical Hold Removal, Trial Initiations, and Committee Recommendations - Analyst Notes on Geron, Zalicus, Northwest Biotherapeutics, Progenics and TG Therapeutics
PR Newswire - Tue Jun 17, 4:30AM CDT
Today, Analysts Review released its analysts' notes regarding Geron Corporation (NASDAQ: GERN), Zalicus Inc. (NASDAQ: ZLCS), Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), Progenics Pharmaceuticals Inc. (NASDAQ: PGNX) and TG Therapeutics, Inc. (NASDAQ: TGTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/3775-100free.
PGNX: 5.66 (+0.06), NWBO: 6.07 (+0.13), ZLCS: 1.18 (+0.03), GERN: 3.03 (unch), TGTX: 13.13 (-0.19)
Short Squeeze Starting in Zalicus (ZLCS) According to WealthMakers.com Report
M2 - Fri Jun 13, 6:54AM CDT
WEALTHMAKERS.COM / www.wealthmakers.com , a Wall Street research and trading firm providing unbiased statistical stock market predictions to empower investors, securities professionals and public company employees to make precise, predictive and profitable trading decisions, has issued a research report on Zalicus (NASDAQ: ZLCS). The report highlights the short term bullish pattern that has emerged, the SqueezeTrigger Price of $1.49 and the projected fundamental valuation of $6.60.
ZLCS: 1.18 (+0.03)
Why Zalicus (ZLCS) Stock Is Surging Today
at The Street - Thu Jun 12, 10:10AM CDT
Zalicus (ZLCS) surged Thursday after Epirus Switzerland announced clinical data from a Phase 3 study of BOW015, a biosimilar infliximab, in patients with active rheumatoid arthritis.
ZLCS: 1.18 (+0.03)
